Research Insight

After discovering a potential molecular "target" for leukemia, Australian researchers say a drug to fight the disease is "in their sights," although it is still very early days. Writing in the journal Blood, they describe how the interaction of...

A recent study by PricewaterhouseCoopers (PwC) examined the future of pharma and revealed essential technological and IT strategies. Developments in manufacturing, research and development (R&D), and IT will shape the future of pharma, as Ingrid Maes of PwC elaborates....

Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics. The drug was discovered and developed by Zydus Cadila, a pharmaceutical company based in India. Zydus...

Trophos and AFM-Telethon (The French Muscular Dystrophy Association) today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology (AAN)...

Adocia (Euronext Paris: FR0011184241 - ADOC) announces positive results from a phase IIa clinical trial evaluating its innovative ultra-fast formulation of insulin Lispro in comparison to Eli Lilly’s Humalog(R) commercial insulin. Adocia’s formulation incorporates proprietary BioChaperone(R) technology which enables...

Immune cells undergo 'spontaneous' changes on a daily basis that could lead to cancers if not for the diligent surveillance of our immune system, Melbourne scientists have found. The research team from the Walter and Eliza Hall Institute found...

Oramed Pharmaceuticals has released results of a Phase IIa clinical trial of its ORMD-0801, an oral insulin capsule for the treatment of type 2 diabetes. The trial was carried out under a US...